Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CXCR2 | P25025 | 5/20 | 0.39 |
| ▸ | ACLY | P53396 | 2/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.34 |
| ▸ | CCR6 | P51684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2770476 | 1.00 | PDK1 (0.41) | PDK1PDK2PDK3PDK4ATM | |
| SCHEMBL2768040 | 0.93 | ATM (0.43) | ATMCNR1CXCR2ACLYCCR1 | |
| SCHEMBL17293593 | 0.90 | ATM (0.40) | ATMCNR1CXCR2ACLYCCR1 | |
| SCHEMBL17293595 | 0.90 | ATM (0.40) | ATMCNR1CXCR2ACLYCCR1 | |
| SCHEMBL17293877 | 0.85 | ATM (0.43) | ATMCNR1CXCR2CCR1KMT2A | |
| SCHEMBL17293472 | 0.82 | CXCR2 (0.40) | ATMCNR1CXCR2ACLYCCR6 | |
| SCHEMBL6562315 | 0.82 | CXCR2 (0.45) | ATMCNR1CXCR2KMT2ATDP1 | |
| SCHEMBL13205457 | 0.82 | ALDH1A1 (0.45) | ATMCXCR2KMT2ATDP1MEN1 | |
| SCHEMBL17309495 | 0.81 | HSD11B1 (0.43) | ATMCNR1CXCR2ACLYKMT2A | |
| SCHEMBL17293683 | 0.80 | TSHR (0.46) | ATMCXCR2KMT2ATDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1272175-B1 | N,N'-DIARYL GUANIDINES AS IL-8 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2010-04-21 | — | — | EP | disclosed |
| EP-1351933-B1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20060084641-A1 | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2006-04-20 | — | — | US | disclosed |
| EP-1351933-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1272175-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20040048897-A1 | Il-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2004-03-11 | — | — | US | disclosed |
| US-6680317-B2 | N-(PHENYL)-N*-(2-HYDROXY-3-AMINOSULFONYLPHENYL)GUANIDINE DERIVATIVES; CHEMOKINE INHIBITORS; RESPIRATORY, CARDIOVASCULAR, RHEUMATIC, BRAIN, AND NERVOUS SYSTEM DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2004-01-20 | — | — | US | disclosed |
| US-20030216375-A1 | Il-8 receptor anatagonists | GLAXOSMITHKLINE LLC | 2003-11-20 | — | — | US | disclosed |
| CN-1452483-A | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 2003-10-29 | — | — | CN | disclosed |
| EP-1351933-A1 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2003-10-15 | — | — | EP | disclosed |
| EP-1272175-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-08 | — | — | EP | disclosed |
| WO-2002057230-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-2001072960-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216375-A1 | Il-8 receptor anatagonists | CXCL8, CCR8, IL1R1 | PDK1 3624/4885PDK2 3735/4885PDK3 3544/4885 |
| US-20040048897-A1 | Il-8 receptor antagonists | CXCL8, CCR8, TLR8 | PDK1 4471/4885PDK2 4257/4885PDK3 3871/4885 |
| US-20060084641-A1 | IL-8 receptor antagonists | CXCL8, CCR8, TLR8 | PDK1 4471/4885PDK2 4257/4885PDK3 3871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.